The Multiple Myeloma Therapeutics Market in Latin America was worth USD 1.08 billion in 2021 and estimated to be growing at a CAGR of 5.33%, to reach USD 1.41 billion by 2026.
Multiple myelomas are a specifically fatal but less common type of blood cancer that affects in eventual patient deteriorations even after therapy and is universally considered as lethal. The incidence of multiple myeloma is increasing with each passing year. The disease mostly affects the aged, assumed the average age of disease start at around 70 years.
Expanding indications of existing drugs, the emergence of new and promising drugs, increasing the incidence of multiple myeloma and increasing use of drugs already on the market are fuelling the growth of the market. Moreover, growth is being driven by the drive to novel drugs in search of higher effectiveness and safety and increasing the use of these high prices medicines for the treatment of the condition. Stringent regulation is the key factor hindering the multiple myeloma therapeutics market.
This research report on the LATAM Multiple Myeloma Therapeutics Market has been segmented and sub-segmented into the following categories
By Treatment Type:
By Drug Type:
By Country:
Regionally, Mexico is dominating the multiple myeloma therapeutics market in the Latin America region and is expected to continue its dominance over the forecast period.
Prominent companies leading in the Latin America Multiple Myeloma Therapeutics Market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd.,TG Therapeutics Inc. and Johnson and Johnson.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Anthracycline antibiotic
5.1.1.2 Alkylating agent
5.1.2 Targeted Therapy
5.1.2.1 Proteasome inhibitor
5.2 By Drug Type
5.2.1 Corticosteroids
5.2.1.1 Dexamethasone (Decadron)
5.2.1.2 Prednisone (Deltasone/Orasone)
5.2.2 Immunomodulatory agents
5.2.2.1 Thalidomide (Thalomid)
5.2.2.2 Lenalidomide (Revlimid)
5.2.2.3 Arsenic trioxide (Trisenox)
5.2.2.4 Plerixafor (Mozobil)
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Mexico
6.4 Argentina
6.5 Rest of Latin America
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)
7.4.1 Failure Rate
7.4.2 Clinical Trial Duration
7.4.3 Clinical Trial Size
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AB Science SA
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 AbbVie Inc.
9.3 Ablynx NV
9.4 Acceleron Pharma Inc.
9.5 IGF Oncology LLC.
9.6 ImmunGene Inc.
9.7 Millennium Pharmaceuticals Inc.
9.8 MimiVax LLC
9.9 Mirna Therapeutics
9.10 RedHill Biopharma Ltd.
9.11 Rhizen Pharmaceuticals S.A.
9.12 Terpenoid Therapeutics Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Anthracycline antibiotic
5.1.1.2 Alkylating agent
5.1.2 Targeted Therapy
5.1.2.1 Proteasome inhibitor
5.2 By Drug Type
5.2.1 Corticosteroids
5.2.1.1 Dexamethasone (Decadron)
5.2.1.2 Prednisone (Deltasone/Orasone)
5.2.2 Immunomodulatory agents
5.2.2.1 Thalidomide (Thalomid)
5.2.2.2 Lenalidomide (Revlimid)
5.2.2.3 Arsenic trioxide (Trisenox)
5.2.2.4 Plerixafor (Mozobil)
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Mexico
6.4 Argentina
6.5 Rest of Latin America
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)
7.4.1 Failure Rate
7.4.2 Clinical Trial Duration
7.4.3 Clinical Trial Size
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AB Science SA
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 AbbVie Inc.
9.3 Ablynx NV
9.4 Acceleron Pharma Inc.
9.5 IGF Oncology LLC.
9.6 ImmunGene Inc.
9.7 Millennium Pharmaceuticals Inc.
9.8 MimiVax LLC
9.9 Mirna Therapeutics
9.10 RedHill Biopharma Ltd.
9.11 Rhizen Pharmaceuticals S.A.
9.12 Terpenoid Therapeutics Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
